Cargando…

Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure

Excessive acetaminophen (APAP) use is one of the most common causes of acute liver failure. Various types of cell death in the damaged liver are linked to APAP-induced hepatotoxicity, and, of these, necrotic cell death of hepatocytes has been shown to be involved in disease pathogenesis. Until recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemoto, Kenji, Hatano, Etsuro, Iwaisako, Keiko, Takeiri, Masatoshi, Noma, Naruto, Ohmae, Saori, Toriguchi, Kan, Tanabe, Kazutaka, Tanaka, Hirokazu, Seo, Satoru, Taura, Kojiro, Machida, Keigo, Takeda, Norihiko, Saji, Shigehira, Uemoto, Shinji, Asagiri, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208088/
https://www.ncbi.nlm.nih.gov/pubmed/25349782
http://dx.doi.org/10.1016/j.fob.2014.08.007
_version_ 1782341074936659968
author Takemoto, Kenji
Hatano, Etsuro
Iwaisako, Keiko
Takeiri, Masatoshi
Noma, Naruto
Ohmae, Saori
Toriguchi, Kan
Tanabe, Kazutaka
Tanaka, Hirokazu
Seo, Satoru
Taura, Kojiro
Machida, Keigo
Takeda, Norihiko
Saji, Shigehira
Uemoto, Shinji
Asagiri, Masataka
author_facet Takemoto, Kenji
Hatano, Etsuro
Iwaisako, Keiko
Takeiri, Masatoshi
Noma, Naruto
Ohmae, Saori
Toriguchi, Kan
Tanabe, Kazutaka
Tanaka, Hirokazu
Seo, Satoru
Taura, Kojiro
Machida, Keigo
Takeda, Norihiko
Saji, Shigehira
Uemoto, Shinji
Asagiri, Masataka
author_sort Takemoto, Kenji
collection PubMed
description Excessive acetaminophen (APAP) use is one of the most common causes of acute liver failure. Various types of cell death in the damaged liver are linked to APAP-induced hepatotoxicity, and, of these, necrotic cell death of hepatocytes has been shown to be involved in disease pathogenesis. Until recently, necrosis was commonly considered to be a random and unregulated form of cell death; however, recent studies have identified a previously unknown form of programmed necrosis called receptor-interacting protein kinase (RIPK)-dependent necrosis (or necroptosis), which is controlled by the kinases RIPK1 and RIPK3. Although RIPK-dependent necrosis has been implicated in a variety of disease states, including atherosclerosis, myocardial organ damage, stroke, ischemia–reperfusion injury, pancreatitis, and inflammatory bowel disease. However its involvement in APAP-induced hepatocyte necrosis remains elusive. Here, we showed that RIPK1 phosphorylation, which is a hallmark of RIPK-dependent necrosis, was induced by APAP, and the expression pattern of RIPK1 and RIPK3 in the liver overlapped with that of CYP2E1, whose activity around the central vein area has been demonstrated to be critical for the development of APAP-induced hepatic injury. Moreover, a RIPK1 inhibitor ameliorated APAP-induced hepatotoxicity in an animal model, which was underscored by significant suppression of the release of hepatic enzymes and cytokine expression levels. RIPK1 inhibition decreased reactive oxygen species levels produced in APAP-injured hepatocytes, whereas CYP2E1 expression and the depletion rate of total glutathione were unaffected. Of note, RIPK1 inhibition also conferred resistance to oxidative stress in hepatocytes. These data collectively demonstrated a RIPK-dependent necrotic mechanism operates in the APAP-injured liver and inhibition of this pathway may be beneficial for APAP-induced fulminant hepatic failure.
format Online
Article
Text
id pubmed-4208088
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-42080882014-10-27 Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure Takemoto, Kenji Hatano, Etsuro Iwaisako, Keiko Takeiri, Masatoshi Noma, Naruto Ohmae, Saori Toriguchi, Kan Tanabe, Kazutaka Tanaka, Hirokazu Seo, Satoru Taura, Kojiro Machida, Keigo Takeda, Norihiko Saji, Shigehira Uemoto, Shinji Asagiri, Masataka FEBS Open Bio Article Excessive acetaminophen (APAP) use is one of the most common causes of acute liver failure. Various types of cell death in the damaged liver are linked to APAP-induced hepatotoxicity, and, of these, necrotic cell death of hepatocytes has been shown to be involved in disease pathogenesis. Until recently, necrosis was commonly considered to be a random and unregulated form of cell death; however, recent studies have identified a previously unknown form of programmed necrosis called receptor-interacting protein kinase (RIPK)-dependent necrosis (or necroptosis), which is controlled by the kinases RIPK1 and RIPK3. Although RIPK-dependent necrosis has been implicated in a variety of disease states, including atherosclerosis, myocardial organ damage, stroke, ischemia–reperfusion injury, pancreatitis, and inflammatory bowel disease. However its involvement in APAP-induced hepatocyte necrosis remains elusive. Here, we showed that RIPK1 phosphorylation, which is a hallmark of RIPK-dependent necrosis, was induced by APAP, and the expression pattern of RIPK1 and RIPK3 in the liver overlapped with that of CYP2E1, whose activity around the central vein area has been demonstrated to be critical for the development of APAP-induced hepatic injury. Moreover, a RIPK1 inhibitor ameliorated APAP-induced hepatotoxicity in an animal model, which was underscored by significant suppression of the release of hepatic enzymes and cytokine expression levels. RIPK1 inhibition decreased reactive oxygen species levels produced in APAP-injured hepatocytes, whereas CYP2E1 expression and the depletion rate of total glutathione were unaffected. Of note, RIPK1 inhibition also conferred resistance to oxidative stress in hepatocytes. These data collectively demonstrated a RIPK-dependent necrotic mechanism operates in the APAP-injured liver and inhibition of this pathway may be beneficial for APAP-induced fulminant hepatic failure. Elsevier 2014-09-06 /pmc/articles/PMC4208088/ /pubmed/25349782 http://dx.doi.org/10.1016/j.fob.2014.08.007 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Takemoto, Kenji
Hatano, Etsuro
Iwaisako, Keiko
Takeiri, Masatoshi
Noma, Naruto
Ohmae, Saori
Toriguchi, Kan
Tanabe, Kazutaka
Tanaka, Hirokazu
Seo, Satoru
Taura, Kojiro
Machida, Keigo
Takeda, Norihiko
Saji, Shigehira
Uemoto, Shinji
Asagiri, Masataka
Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure
title Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure
title_full Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure
title_fullStr Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure
title_full_unstemmed Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure
title_short Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure
title_sort necrostatin-1 protects against reactive oxygen species (ros)-induced hepatotoxicity in acetaminophen-induced acute liver failure
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208088/
https://www.ncbi.nlm.nih.gov/pubmed/25349782
http://dx.doi.org/10.1016/j.fob.2014.08.007
work_keys_str_mv AT takemotokenji necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT hatanoetsuro necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT iwaisakokeiko necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT takeirimasatoshi necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT nomanaruto necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT ohmaesaori necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT toriguchikan necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT tanabekazutaka necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT tanakahirokazu necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT seosatoru necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT taurakojiro necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT machidakeigo necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT takedanorihiko necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT sajishigehira necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT uemotoshinji necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure
AT asagirimasataka necrostatin1protectsagainstreactiveoxygenspeciesrosinducedhepatotoxicityinacetaminopheninducedacuteliverfailure